In diseases such as breast cancer the primary clinical classifications relate to the expression of hormone receptors (estrogen receptor: ER; and progesterone receptor: PR) or the overexpression of Erb-B2 receptor tyrosine kinase (HER2), as these features can be directly targeted with therapeutic agents. This evidence concerns the gene PGR and breast cancer.